Immunocore Holdings plcIMCREarnings & Financial Report
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
IMCR Q3 2025 Key Financial Metrics
Revenue
$103.7M
Gross Profit
$103.2M
Operating Profit
$-7.2M
Net Profit
$-177.0K
Gross Margin
99.5%
Operating Margin
-6.9%
Net Margin
-0.2%
YoY Growth
29.2%
EPS
$0.00
Financial Flow
Immunocore Holdings plc Q3 2025 Financial Summary
Immunocore Holdings plc reported revenue of $103.7M for Q3 2025, with a net profit of $-177.0K (-0.2% margin). Cost of goods sold was $513.0K, operating expenses totaled $110.4M.
Key Financial Metrics
| Total Revenue | $103.7M |
|---|---|
| Net Profit | $-177.0K |
| Gross Margin | 99.5% |
| Operating Margin | -6.9% |
| Report Period | Q3 2025 |
Immunocore Holdings plc Annual Revenue by Year
Immunocore Holdings plc annual revenue history includes year-by-year totals (for example, 2024 revenue was $310.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $310.2M |
Income Statement
| Q2 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $59.8M | $70.5M | $75.4M | $80.2M | $84.1M | $93.9M | $98.0M | $103.7M |
| YoY Growth | N/A | N/A | 26.2% | N/A | N/A | 33.2% | 29.9% | 29.2% |
Balance Sheet
| Q2 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | N/A | $994.0M | $1.02B | $1.08B | $1.01B | $1.03B | $1.08B | $1.10B |
| Liabilities | N/A | $634.5M | $664.2M | $706.8M | $648.8M | $649.5M | $693.9M | $705.9M |
| Equity | $351.4M | $359.5M | $359.1M | $377.8M | $360.7M | $378.5M | $388.5M | $396.6M |
Cash Flow
| Q2 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $45000 | $-4.6M | $23.5M | $21.1M | $-14.0M | $435000 | $26.0M | $-4.5M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M